AO 120 (Rev. 08/10)

TO:	Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court for the District of Delaware on the following

☐ Trademarks or ☒ Patents. (☐ the patent action involves 35 U.S.C. § 292.):

DOCKET NO.	DATE FILED 12/9/2014	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF ASTRAZENECA AB		DEFENDANT AUROBINDO PHARMA LTD., and AUROBINDO PHARMA U.S.A., INC.

	PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1	RE 44,186	4/30/2013	AstraZeneca AB
2			
3			
4			
5			

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY ☐ Amendment ☐ Answer ☐ Cross Bill ☐ Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

Judgment - See attached

CLERK John A Cerino, Clerk United States District Court 844 N. King Street, Unit 18 Wilmington, DE 19801	(BY) DEPUTY CLERK	DATE 2/2/17

Copy 1—Upon initiation of action, mail this copy to Director **Copy 3—Upon termination of action, mail this copy to Director**
Copy 2—Upon filing document adding patent(s), mail this copy to Director **Copy 4—Case file copy**

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ASTRAZENECA AB,	)	
	)	
Plaintiff,	)	
	)	
v.	)	
	)	C.A. No. 14-664-GMS
AUROBINDO PHARMA LTD., et al.	)	**(CONSOLIDATED)**
	)	
Defendants.	)	

JUDGMENT

This action came before the Court for a three-day bench trial on September 19th, 2016. The issues have been tried and the parties filed Proposed Findings of Fact and Conclusions of Law shortly thereafter (D.I. 373, 374). The court issued a Memorandum and Order (D.I. 383, 384) ("Bench Opinion") on February 2, 2017. Therefore,

IT IS HEREBY ORDERED AND ADJUDGED that, in accordance with this Court's Bench Opinion, final judgment is hereby entered in favor of plaintiff AstraZeneca AB, and against defendants Aurobindo Pharma Ltd., Aurobindo Pharma U.S.A., Wockhardt Bio AG, Wochardt USA LLC, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sun Pharma Global FZE, Mylan Pharmaceuticals Inc., Watson Laboratories, Inc., and Actavis Laboratories FL, Inc., ("Defendants") finding that:

1. Claims 25 and 26 of the RE44,186 patent are not invalid due to obviousness.
2. Pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of the approval of the Defendants' respective Abbreviated New Drug Applications seeking permission to market generic saxagliptin hydrochloride tablets and saxagliptin hydrochloride and metformin hydrochloride extended-release tablets shall be no earlier than the expiration

date of U.S. Patent No. RE44,186, including any extensions and/or additional periods of exclusivity to which Plaintiff is or becomes entitled; and

3. Defendants and each of their respective directors, officers, agents, servants, and employees, and those acting in privity or concert with them, are permanently enjoined from making, using, offering to sell, or selling in the United States, or importing into the United States their respective generic saxagliptin hydrochloride tablets and saxagliptin hydrochloride and metformin hydrochloride extended-release tablets until after the expiration date of U.S. Patent No. RE44,186, including any extensions and/or additional periods of exclusivity to which Plaintiff is or becomes entitled; and

4. The Clerk of Court is directed to close this case.

Dated: February 2, 2017

UNITED STATES DISTRICT JUDGE